Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Brunner

Showing results (21-30 of 905) with videos related to

Pageof 91
Sort By:
Journal of Human Hypertension|August 1, 1993
Role of vasoactive peptides in blood pressure controlH R Brunner
Revue Medicale De La Suisse Romande|December 1, 1977
[Causes favoring urinary infections and their treatment]H R Brunner
Journal of Human Hypertension|April 23, 2002
The new oral angiotensin II antagonist olmesartan medoxomil: a concise overviewHans R Brunner
Vascular Health and Risk Management|February 28, 2007
Olmesartan medoxomil: current status of its use in monotherapyHans R Brunner
Revue Medicale De La Suisse Romande|September 1, 1976
[Is prevention of chronic renal insufficiency possible?]H R Brunner
American Journal of Hypertension|January 23, 1998
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerationsH R Brunner
American Journal of Hypertension|June 2, 1998
Endothelin inhibition as a biologic target for treating hypertensionH R Brunner
American Journal of Hypertension|November 20, 1997
Introduction: an easy approach to cardiovascular protectionJ R Brunner
Kidney International|August 1, 1992
ACE inhibitors in renal diseaseH R Brunner
Arzneimittel-Forschung|December 1, 1974
[Absorption, distribution and excretion of penicillin V in rats. 2. Compartment studies]H Niedermüller, R Brunner
Pageof 91

Showing results (21-30 of 905) with videos related to

Sort By:
Pageof 91
Journal of Human Hypertension|August 1, 1993
Role of vasoactive peptides in blood pressure controlH R Brunner
Revue Medicale De La Suisse Romande|December 1, 1977
[Causes favoring urinary infections and their treatment]H R Brunner
Journal of Human Hypertension|April 23, 2002
The new oral angiotensin II antagonist olmesartan medoxomil: a concise overviewHans R Brunner
Vascular Health and Risk Management|February 28, 2007
Olmesartan medoxomil: current status of its use in monotherapyHans R Brunner
Revue Medicale De La Suisse Romande|September 1, 1976
[Is prevention of chronic renal insufficiency possible?]H R Brunner
American Journal of Hypertension|January 23, 1998
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerationsH R Brunner
American Journal of Hypertension|June 2, 1998
Endothelin inhibition as a biologic target for treating hypertensionH R Brunner
American Journal of Hypertension|November 20, 1997
Introduction: an easy approach to cardiovascular protectionJ R Brunner
Kidney International|August 1, 1992
ACE inhibitors in renal diseaseH R Brunner
Arzneimittel-Forschung|December 1, 1974
[Absorption, distribution and excretion of penicillin V in rats. 2. Compartment studies]H Niedermüller, R Brunner
Pageof 91